Lakefront Biotherapeutics NV (LKFT) - Total Liabilities
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) has total liabilities worth $119.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see balance sheet size of Lakefront Biotherapeutics NV.
Lakefront Biotherapeutics NV - Total Liabilities Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's total liabilities have evolved over time, based on quarterly financial data. Explore Lakefront Biotherapeutics NV long-term investment allocation to see how much of total assets are deployed in long-term investments.
Lakefront Biotherapeutics NV Competitors by Total Liabilities
The table below lists competitors of Lakefront Biotherapeutics NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Costamare Inc
NYSE:CMRE
|
USA | $1.72 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
India | Rs18.07 Billion |
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
China | CN¥125.45 Billion |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
China | CN¥3.59 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥31.19 Billion |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
China | CN¥14.55 Billion |
|
Yankershop Food Co Ltd
SHE:002847
|
China | CN¥2.10 Billion |
|
Veridis Environment Ltd
TA:VRDS
|
Israel | ILA3.16 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Lakefront Biotherapeutics NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check asset resilience ratio of Lakefront Biotherapeutics NV to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lakefront Biotherapeutics NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual total liabilities of Lakefront Biotherapeutics NV from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.65 Million | -86.22% |
| 2024-12-31 | $1.24 Billion | -20.68% |
| 2023-12-31 | $1.56 Billion | -29.28% |
| 2022-12-31 | $2.21 Billion | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more